Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
about
Bioresorbable vascular scaffolds technology: current use and future developmentsTwelve months clinical outcome after bioresorbable vascular scaffold implantation in patients with stable angina and acute coronary syndrome. Data from the Polish National RegistryBioresorbable Stents in PCI.Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTsSustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014-2015.Clinical implications of blood-material interaction and drug eluting stent polymers in review.Bioresorbable drug-eluting scaffolds for treatment of vascular disease.Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up.Reviewing hybrid coronary revascularization: challenges, controversies and opportunities.Bioresorbable vascular scaffolds-what does the future bring?Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.Dual antiplatelet therapy after coronary stenting.Bioresorbable Polymers and Stent Devices.Drug-eluting balloons in coronary interventions: the quiet revolution?Bioresorbable Scaffolds for Coronary Artery Disease.Impact of Clinical Presentation on Early Vascular Healing After Bioresorbable Vascular Scaffold Implantation.Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials.Acute Coronary Stent Thrombosis in Modern Era: Etiology, Treatment, and Prognosis.The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease.Living history of medicine: vascular scaffolding, from dream to reality.Use of bioresorbable vascular scaffold: a meta-analysis of patients with coronary artery disease.Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients.Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice.Bioresorbable vascular scaffolds-time to vanish?Overlapping meta-analyses of bioresorbable vascular scaffolds versus everolimus-eluting stents: bringing clarity or confusion?Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm.Bioresorbable vascular scaffolds for complex coronary anatomies: "Icarus' flight" for interventional cardiologists?First generation bioresorbable vascular scaffolds: do they hold the promise?Adverse events with bioresorbable vascular scaffolds in routine percutaneous coronary interventions: "coup de théâtre" or unfinished play?Bioresorbable scaffolds and drug-eluting balloons for the management of spontaneous coronary artery dissections.Bioresorbable vascular scaffold: promises and the fallen child-as-king?Bioresorbable drug eluting scaffolds-are bioresorbable stents ready for today's clinical practice?Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis.Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?Patient-Specific Modeling of Stented Coronary Arteries Reconstructed from Optical Coherence Tomography: Towards a Widespread Clinical Use of Fluid Dynamics Analyses.Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea.Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary.Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?Bioresorbable Scaffolds in Coronary Intervention: Unmet Needs and Evolution.
P2860
Q26741147-C075C084-8945-444B-B89C-026512FB49B4Q31106727-9D7EB3BA-6838-49DA-97DE-50F01917AA30Q36055029-54C37E48-47F0-48EF-B4BF-CDA81E1C6C8AQ36395245-D364996A-9642-49A8-82EF-BACC46F93B2FQ37285036-E6FF6BCB-4326-430A-A1AB-599DF69C5E83Q37463810-C462282B-1501-4770-9DCE-E84E50943812Q38645043-D33833AD-0B7D-43FC-9B0B-AC1DC2A3019FQ38728978-78F226EB-7AAC-45C6-AB84-641D2FE5126DQ38733043-28565EE2-C294-46C6-95A9-7B00B5F3DC79Q38797481-4D575B6A-1656-4DBA-B04B-3AC1D6A1268DQ38822091-4B89CDE5-1DF3-4346-BFD8-423059D4805CQ38824733-3F814680-A79B-4D2A-B99E-3254493264A0Q38866836-01CD27C8-48AA-404C-9398-6E57A4D199FDQ38919254-B244D306-450C-47F9-B9F8-84AF3B9454A6Q38975708-D4780E3E-4D36-4DB0-B6AA-B8012C237F07Q39097196-8505A221-E72A-47A6-8788-D355A3C7DA18Q39146294-3C27DF34-9A0D-4E57-8EE1-656D20778BFAQ39254915-61DACF38-8B31-498F-B734-13AAF1C65659Q39284272-53FB1238-04C9-44AD-A97A-79F99648E405Q39465229-49A8E37E-DBD6-475B-8A1C-F24F040F4E06Q40080413-78C43B1B-D965-4384-B6E9-4A4244500609Q41028884-5BC1653F-DB0E-4FDD-9179-34A7334553D2Q41038135-AF8A0EC0-17B5-4212-B915-E058525D2C09Q41607661-FC22CA52-3CDA-4B69-BB9D-728375D52F22Q41860479-6430C3ED-1438-4C1A-997E-C8E9494A6B21Q41901711-147C256E-C284-4355-B4BB-60A279E007FCQ42120824-1416359F-45F5-4AA1-86BE-DA55D640E0F3Q42333628-95111C27-3B1F-46F2-9FE5-C6CD498E8D8CQ42357310-A653FED5-81F9-4084-9088-D445FFE32F0AQ42357323-A9650E2B-A86D-4D90-B93B-4C0FE6187306Q42369279-23B9ED40-3309-4E87-8EB8-7E415A45DA2BQ42381193-6F0FC28D-5A50-47E8-84A9-0A20615965B2Q42751286-7C7C1424-4A93-4AA8-8BA6-1A8B260CFAEBQ45330989-83140042-18E9-4E2D-B848-A733D9650EDEQ47131528-4217FCE2-E0D6-4427-AB8A-85ED834D924BQ47215222-54DF5900-2697-4F0E-90AA-1E870680E9ADQ47376464-5C6D0D84-0C55-43E4-939F-B0FFD27AEB85Q47579904-7668C186-29B9-4A98-B577-9B305AD474AEQ47686997-F98FE00C-2052-4475-9482-50BBEBA1AA33Q47738961-8E073AFA-845E-4303-AE56-C6E84C61BD6B
P2860
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Everolimus-eluting bioresorbab ...... randomised controlled trials.
@en
type
label
Everolimus-eluting bioresorbab ...... randomised controlled trials.
@en
prefLabel
Everolimus-eluting bioresorbab ...... randomised controlled trials.
@en
P2093
P50
P1433
P1476
Everolimus-eluting bioresorbab ...... randomised controlled trials.
@en
P2093
Gjin Ndrepepa
Janika Repp
Jens Wiebe
Massimiliano Fusaro
Salvatore Cassese
Sebastian Kufner
Takeshi Kimura
P304
P356
10.1016/S0140-6736(15)00979-4
P407
P577
2015-11-16T00:00:00Z